Cytokine-Induced Killer Cells in Combination with Heat Shock Protein 90 Inhibitors Functioning via the Fas/FasL Axis...

Area of Science:

• Immunology
• Oncology
• Molecular Biology

Background:

• Cancer immunotherapy, including cytokine-induced killer (CIK) cell therapy, is an area of active research.
• Heat shock protein (HSP) 90 inhibitors have shown promise in preclinical and clinical cancer studies.
• Burkitt's lymphoma (BL) is an aggressive non-Hodgkin lymphoma with specific therapeutic challenges.

Purpose of the Study:

• To evaluate the compatibility and efficacy of combining CIK cells with HSP90 inhibitors against Burkitt's lymphoma (BL) cells.
• To elucidate the mechanisms underlying the combined therapeutic effect.
• To assess the clinical relevance of HSP90 family gene expression in BL patient survival.

Main Methods:

• Cytotoxicity assays were performed using CIK cells and BL cells in combination with HSP90 inhibitors (17-DMAG and ganetespib).
• Flow cytometry was used to analyze the expression of cell surface markers, including NKG2D and Fas.
• Caspase activity assays were conducted to assess apoptosis induction.
• Analysis of HSP90 family gene expression in relation to overall survival data from BL patients.

Main Results:

• CIK cell-mediated cytotoxicity against BL cells was significantly augmented by HSP90 inhibitors 17-DMAG and ganetespib.
• CIK cell activity was not diminished by blocking NKG2D, suggesting an alternative activation pathway.
• Increased expression of Fas on BL cells was observed, leading to caspase 3/7-dependent apoptosis.
• High expression of HSP90 family genes (HSP90AA1, HSP90AB1, HSP90B1, Hsp40, Hsp70, Hsp110) correlated with reduced overall survival in BL patients.

Conclusions:

• CIK cells, alone or with HSP90 inhibitors, target BL cells primarily through the Fas-FasL pathway, not NKG2D.
• Combined CIK cell and HSP90 inhibitor therapy demonstrates potential for treating BL.
• HSP90 family gene expression serves as a prognostic marker for BL patient survival.